PP
ORIC icon

PDT Partners’s Oric Pharmaceuticals ORIC Stock Holding History

PDT Partners’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-66,945
Closed -$300K – 1017
2022
Q2 		$300K Sell
66,945
-11,875
-15% -$47.4K 0.03% 743
2022
Q1 		$421K Buy
78,820
+45,763
+138% +$412K 0.04% 629
2021
Q4 		$486K Buy
+33,057
New +$515K 0.04% 532

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

PDT Partners's ORIC Position: Q3 2022 in Review

PDT Partners sold out of Oric Pharmaceuticals (ORIC) in Q3 2022, closing a stake of 66,945 shares — an estimated $300K sold.

PDT Partners first reported a position in ORIC in Q4 2021 and held it in 3 quarters. The position peaked at $486K in Q4 2021. 76 funds tracked by Wall St. Rank hold ORIC as of Q3 2022.

  • PDT Partners reported no remaining Oric Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • PDT Partners sold 66,945 Oric Pharmaceuticals shares in Q3 2022, an estimated $300K.
  • PDT Partners first reported a position in Oric Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • PDT Partners's Oric Pharmaceuticals position peaked at $486K in Q4 2021.
  • 76 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2022.

Based on PDT Partners's 13F filing for Q3 2022, filed 14 Nov 2022.